1942 related articles for article (PubMed ID: 25865049)
1. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
[TBL] [Abstract][Full Text] [Related]
2. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
[TBL] [Abstract][Full Text] [Related]
3. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
[TBL] [Abstract][Full Text] [Related]
4. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
[TBL] [Abstract][Full Text] [Related]
5. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.
Promrat K; Kleiner DE; Niemeier HM; Jackvony E; Kearns M; Wands JR; Fava JL; Wing RR
Hepatology; 2010 Jan; 51(1):121-9. PubMed ID: 19827166
[TBL] [Abstract][Full Text] [Related]
8. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.
Lee YM; Low HC; Lim LG; Dan YY; Aung MO; Cheng CL; Wee A; Lim SG; Ho KY
Gastrointest Endosc; 2012 Oct; 76(4):756-60. PubMed ID: 22840293
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
10. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
Bazerbachi F; Vargas EJ; Rizk M; Maselli DB; Mounajjed T; Venkatesh SK; Watt KD; Port JD; Basu R; Acosta A; Hanouneh I; Gara N; Shah M; Mundi M; Clark M; Grothe K; Storm AC; Levy MJ; Abu Dayyeh BK
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):146-154.e4. PubMed ID: 32360804
[TBL] [Abstract][Full Text] [Related]
11. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
[TBL] [Abstract][Full Text] [Related]
12. Validation of the non-alcoholic fatty liver disease activity score.
Hjelkrem M; Stauch C; Shaw J; Harrison SA
Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
[TBL] [Abstract][Full Text] [Related]
13. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
Younossi ZM; Stepanova M; Rafiq N; Makhlouf H; Younoszai Z; Agrawal R; Goodman Z
Hepatology; 2011 Jun; 53(6):1874-82. PubMed ID: 21360720
[TBL] [Abstract][Full Text] [Related]
14. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.
Vilar-Gomez E; Yasells-Garcia A; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Villa-Jimenez O; Friedman SL; Diago M; Romero-Gomez M
Hepatology; 2016 Jun; 63(6):1875-87. PubMed ID: 26849287
[TBL] [Abstract][Full Text] [Related]
16. Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study.
Tapper EB; Lai M
Hepatology; 2016 Apr; 63(4):1184-9. PubMed ID: 26698379
[TBL] [Abstract][Full Text] [Related]
17. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
Chan WK; Ida NH; Cheah PL; Goh KL
J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.
Dixon JB; Bhathal PS; Hughes NR; O'Brien PE
Hepatology; 2004 Jun; 39(6):1647-54. PubMed ID: 15185306
[TBL] [Abstract][Full Text] [Related]
20. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial.
Alam S; Kabir J; Mustafa G; Gupta U; Hasan SK; Alam AK
Saudi J Gastroenterol; 2016; 22(1):69-76. PubMed ID: 26831610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
